Pars Plana VitrectomyNCT07396831
Necessity of Post-operative Eye Drops
An observational study of Pars Plana Vitrectomy and Scleral Buckling, run by Loma Linda University at 1 site in United States.
Trial summary
The goal of this clinical study is to determine if antibiotic eye drops are needed after retinal surgery to prevent infection. Currently, patients are prescribed antibiotic eye drops to use for several weeks after they undergo retina surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pars Plana Vitrectomy, Scleral Buckling, Surgical Outcomes
- How many people
- 48 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Apr 2024to 22 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients from a single vitreoretinal surgeon at Loma Linda University Medical Center.
Who may be able to join
- Patients undergoing Pars plana vitrectomy and/or scleral buckling
Who cannot join
- Patients younger than 18
- Patients undergoing Pars plana vitrectomy for endophthalmitis
- Patients having combined intraocular lens and vitrectomy surgery
- Patients that received a cornea scrape during surgery
Trial locations and contacts
1 site in 1 country.
United States1 site
Loma Linda University Eye Institute
Loma Linda, California, 92354
About this study
Official title: Safety of Retina Surgery Without Postoperative Eye Drops
The goal of this clinical study is to determine if antibiotic eye drops are needed after retinal surgery to prevent infection. Currently, patients are prescribed antibiotic eye drops to use for several weeks after they undergo retina surgery. The main question that we are trying to answer is:
- Are postoperative eye drops necessary to prevent eye infections after retina surgery? Patients will still receive steroid drops after their surgery to control inflammation. Additionally, patients will have regular follow up with their eye surgeon to monitor for the signs and symptoms of eye infection.
- Keywords
- Pars plana vitrectomy, Scleral buckling, Infection prophylaxis, Topical antibiotics
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence of endophthalmitis
The primary outcome of this study is the presence of endophthalmitis 30 days after pars plana vitrectomy and/or scleral buckling without the use of post-operative antibiotics.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start9 Apr 2024
- Primary completion22 Dec 2025
- Study completion22 Dec 2025
Why it stopped: PI left institution. No new PI.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pars Plana VitrectomyStudies of the same condition, open and under way.
- More trials run by Loma Linda UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Loma Linda University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Bailey Shen, Doctor of Medicine, Principal investigator, Loma Linda University Eye Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07396831
- Sponsor's protocol ID
- 5230480
- Status last verified
- Feb 2026
- First submitted
- 2 Feb 2026
- Last updated
- 9 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Only IPD used in the results publication will be shared
Publications
Dave VP, Pathengay A, Schwartz SG, Flynn HW Jr. Endophthalmitis following pars plana vitrectomy: a literature review of incidence, causative organisms, and treatment outcomes. Clin Ophthalmol. 2014 Oct 31;8:2183-8. doi: 10.2147/OPTH.S71293. eCollection 2014.
PubMed 25382968
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety of Retina Surgery Without Postoperative Eye Drops
- ClinicalTrials.gov ID
- NCT07396831
- Acronym / sponsor ID
- 5230480
- Keywords
- Pars plana vitrectomy, Scleral buckling, Infection prophylaxis, Topical antibiotics
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: PI left institution. No new PI.
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Loma Linda UniversityUniversity, hospital or other
- Study start
- 9 Apr 2024 (actual)
- Primary completion
- 22 Dec 2025 (actual)
- Study completion
- 22 Dec 2025 (actual)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical study is to determine if antibiotic eye drops are needed after retinal surgery to prevent infection. Currently, patients are prescribed antibiotic eye drops to use for several weeks after they undergo retina surgery. The main question that we are trying to answer is:
- Are postoperative eye drops necessary to prevent eye infections after retina surgery? Patients will still receive steroid drops after their surgery to control inflammation. Additionally, patients will have regular follow up with their eye surgeon to monitor for the signs and symptoms of eye infection.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients from a single vitreoretinal surgeon at Loma Linda University Medical Center.
Key inclusion criteria (1 listed)
- Patients undergoing Pars plana vitrectomy and/or scleral buckling
Key exclusion criteria (4 listed)
- Patients younger than 18
- Patients undergoing Pars plana vitrectomy for endophthalmitis
- Patients having combined intraocular lens and vitrectomy surgery
- Patients that received a cornea scrape during surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Presence of endophthalmitis
Time frame: 30 days
The primary outcome of this study is the presence of endophthalmitis 30 days after pars plana vitrectomy and/or scleral buckling without the use of post-operative antibiotics.
Results and safety
The study was stopped early (reason given: PI left institution. No new PI.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Background: PubMed 25382968Dave VP, Pathengay A, Schwartz SG, Flynn HW Jr. Endophthalmitis following pars plana vitrectomy: a literature review of incidence, causative organisms, and treatment outcomes. Clin Ophthalmol. 2014 Oct 31;8:2183-8. doi: 10.2147/OPTH.S71293. eCollection 2014.
- Individual participant dataSharing planned: Yes. Only IPD used in the results publication will be shared
Related trials for Pars Plana Vitrectomy
Not yet recruitingPhase 4
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Not yet recruitingPhase 2/3
Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)
Retinal Detachment Rhegmatogenous
Active, not recruiting
Outcomes of Macular Hole Surgery With Inverted Flap With vs Without Post op Posturing With SF6 in Macular Hole More Than 400 Micrometres
Macular Hole
Active, not recruiting
Comparison of Visual Outcomes of Pars Plana Vitrectomy With and Without Injection Clexane for Rhegmatogenous Retinal Detachment Proliferative Vitreoretinopathy
Rhegmatogenous Retinal Detachment With Grade C Proliferative Vitreoretinopathy
Recruiting
Predictors of Vitrectomy Outcomes in Myopic Foveoschisis
Myopic Traction Maculopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bailey Shen, Doctor of Medicine principal investigator
Loma Linda University Eye Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pars Plana Vitrectomy and Scleral Buckling, run by Loma Linda University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: PI left institution. No new PI.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence of endophthalmitis (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07396831, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.